MedPath

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000963
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To evaluate the effectiveness, safety, and tolerance of two doses of didanosine (ddI) in the treatment of children with symptomatic HIV disease who have had to discontinue zidovudine (AZT) because of intolerance and/or who have experienced progressive disease while on AZT.

The progression of immunodeficiency due to HIV infection can be delayed by using AZT. The benefits of AZT in adults with AIDS and severe AIDS-related complex (ARC) appear to last for approximately 12 to 18 months, at which time most patients have progressive deterioration. Recently published literature has described a reduced sensitivity of HIV isolated from patients after prolonged AZT treatment. Although the clinical significance of this is unclear, it makes the development of new antiretroviral drugs important.

Detailed Description

The progression of immunodeficiency due to HIV infection can be delayed by using AZT. The benefits of AZT in adults with AIDS and severe AIDS-related complex (ARC) appear to last for approximately 12 to 18 months, at which time most patients have progressive deterioration. Recently published literature has described a reduced sensitivity of HIV isolated from patients after prolonged AZT treatment. Although the clinical significance of this is unclear, it makes the development of new antiretroviral drugs important.

Children who show AZT intolerance and/or progressive disease after 6 months of AZT therapy receive oral ddI at 1 of 2 doses for a minimum of 48 weeks, with a 48-week extension. Patients are seen for clinical and laboratory evaluations at scheduled times during the study. (Per 5/12/92 amendment, new patients will not be enrolled in the pharmacokinetics studies.) Per 10/31/94 amendment: Patients are eligible to receive blinded study drug for an additional 8-16 weeks after the final on-study visit, but no later than 2/15/95.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (52)

Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Cook County Hosp.

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Univ. of Illinois College of Medicine at Chicago, Dept. of Peds.

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Chicago Children's CRS

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

HMS - Children's Hosp. Boston, Div. of Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Texas Children's Hosp. CRS

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

UW School of Medicine - CHRMC

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Univ. of Miami Ped. Perinatal HIV/AIDS CRS

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

DUMC Ped. CRS

๐Ÿ‡บ๐Ÿ‡ธ

Durham, North Carolina, United States

UCSF Pediatric AIDS CRS

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Children's Hospital of Michigan NICHD CRS

๐Ÿ‡บ๐Ÿ‡ธ

Detroit, Michigan, United States

Usc La Nichd Crs

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Long Beach Memorial Med. Ctr., Miller Children's Hosp.

๐Ÿ‡บ๐Ÿ‡ธ

Long Beach, California, United States

Univ. of Connecticut Health Ctr., Dept. of Ped.

๐Ÿ‡บ๐Ÿ‡ธ

Farmington, Connecticut, United States

Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.

๐Ÿ‡บ๐Ÿ‡ธ

Oakland, California, United States

UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

UCSD Maternal, Child, and Adolescent HIV CRS

๐Ÿ‡บ๐Ÿ‡ธ

San Diego, California, United States

Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

Children's National Med. Ctr., ACTU

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Howard Univ. Washington DC NICHD CRS

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

Tulane/LSU Maternal/Child CRS

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

BMC, Div. of Ped Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

UMDNJ - Robert Wood Johnson

๐Ÿ‡บ๐Ÿ‡ธ

New Brunswick, New Jersey, United States

St. Joseph's Hosp. & Med. Ctr. of New Jersey

๐Ÿ‡บ๐Ÿ‡ธ

Paterson, New Jersey, United States

Children's Hospital at Albany Medical Center, Dept. of Peds.

๐Ÿ‡บ๐Ÿ‡ธ

Albany, New York, United States

Bronx-Lebanon Hosp. IMPAACT CRS

๐Ÿ‡บ๐Ÿ‡ธ

Bronx, New York, United States

SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS

๐Ÿ‡บ๐Ÿ‡ธ

Brooklyn, New York, United States

Metropolitan Hosp. NICHD CRS

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

North Shore-Long Island Jewish Health System, Dept. of Peds.

๐Ÿ‡บ๐Ÿ‡ธ

Great Neck, New York, United States

Schneider Children's Hosp., Div. of Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

New Hyde Park, New York, United States

NYU Med. Ctr., Dept. of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Harlem Hosp. Ctr. NY NICHD CRS

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Columbia IMPAACT CRS

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Univ. of Rochester ACTG CRS

๐Ÿ‡บ๐Ÿ‡ธ

Rochester, New York, United States

Incarnation Children's Ctr.

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

SUNY Upstate Med. Univ., Dept. of Peds.

๐Ÿ‡บ๐Ÿ‡ธ

Syracuse, New York, United States

SUNY Stony Brook NICHD CRS

๐Ÿ‡บ๐Ÿ‡ธ

Stony Brook, New York, United States

St. Christopher's Hosp. for Children

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Case CRS

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

The Children's Hosp. of Philadelphia IMPAACT CRS

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Med. Univ. of South Carolina, Div. of Ped. Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Children's Med. Ctr. Dallas

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Univ. Hosp. Ramรณn Ruiz Arnau, Dept. of Peds.

๐Ÿ‡ต๐Ÿ‡ท

Bayamon, Puerto Rico

San Juan City Hosp. PR NICHD CRS

๐Ÿ‡ต๐Ÿ‡ท

San Juan, Puerto Rico

Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS

๐Ÿ‡ต๐Ÿ‡ท

San Juan, Puerto Rico

Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Torrance, California, United States

WNE Maternal Pediatric Adolescent AIDS CRS

๐Ÿ‡บ๐Ÿ‡ธ

Worcester, Massachusetts, United States

Baystate Health, Baystate Med. Ctr.

๐Ÿ‡บ๐Ÿ‡ธ

Springfield, Massachusetts, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath